Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) on Wednesday announced it has signed an authorized sales agent agreement with Irudigi to bring its cardiac-imaging technology to France.
Irudigi, based in France, is a medical imaging and health-care information technology company. Under the sales agreement, Irudigi will help bring to market Ventripoint’s VMS+ device that uses artificial intelligence to streamline volumetric measurements of all four heart chambers with conventional ultrasound, according to a statement.
“Irudigi's knowledge of the cardiac market in France and experience within the imaging industry will be an asset to the business as we continue to grow,” said Ventripoint CEO George Adams.
Irudigi CEO Pierre Zavattero said that France lacks magnetic resonance imaging (MRI) scanners, which heightens the need for Ventripoint’s technology.
“There are over 1 million people suffering from cardiac impairments in France, a number that grew by 30% over the last decade,” he said. “The combination of low MRI coverage, a growing number of patients, and financial incentives make the Ventripoint VMS+ a perfectly suited solution for the French market.”
Ventripoint, based on Toronto, noted in its statement that neighbors Germany, Italy and Spain have at least twice as many MRIs than France. Consequently, current waiting times for MRIs are over a month in France, while they are only 1 to 2 weeks for echography, with a significantly shorter examination time, the company added.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham